AstraZeneca brings 8 presentations to BPI 2026 in Boston. Its program pairs continuous and intensified processing with predictive process control. Work covers high-throughput chemically defined media and feed optimization, predicting the impact of diversions in a dynamic continuous process, and the cell culture levers that shape antibody-drug conjugate loading.
| Organization | BPI 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | 2 Senior Scientist · 1 Director Manufacturing Science & Technology · 1 Executive Director of Bioprocess Technology and Engineering · 1 Director · 1 other speaker |
Global pharmaceutical company developing and manufacturing biologics, including antibodies and antibody-drug conjugates. | Panel Tue Sep 22 11:30am–12:00pm Keynote Wed Sep 23 9:00am–9:30am Keynote Wed Sep 23 5:00pm–5:45pm PLENARY KEYNOTE: Integrated and Continuous Bioprocessing: what’s holding us back, and where do we go from here? Upstream & Cell CultureDownstream Processing Talk Thu Sep 24 12:00pm–12:30pm Talk Fri Sep 25 11:15am–11:45am Talk Fri Sep 25 2:00pm–2:30pm Talk Fri Sep 25 2:30pm–3:30pm Talk Fri Sep 25 2:30pm–3:30pm |
Instantly find 20 buyers from AstraZeneca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect or the BioProcess International Conference & Exhibition. Submit a correction